Todos os estudos
RecrutamentoExploratório terapêutico (Fase II)Intervencionista

A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study

This study, called DANTE, is for people with a type of blood cancer called chronic myeloid leukaemia (CML). It’s investigating a new way to manage CML where patients might be able to stop their medication (either Tasigna or Scemblix) after successful initial treatment. The study has two main stages where participants will try to enter a 'treatment-free remission', meaning they are well without needing daily drugs. If the cancer starts to become detectable again, they may go back onto treatment or switch to a combination of medications. The goal is to see how many people can successfully stop treatment and remain healthy, and what happens if they need to restart or change their medicine.

Em resumo

Status
Recrutamento
Fase
Exploratório terapêutico (Fase II)
Patrocinador
Novartis Farma S.p.A.
Meta de inscrição
170
Iniciar
09 Sep 2024

Sobre o que é este estudo?

This clinical trial, called DANTE, is for individuals living with Chronic Myeloid Leukaemia (CML). CML is a type of cancer that affects the blood and bone marrow. While there are effective medications for CML, many people wonder if they can eventually stop taking these drugs and still remain healthy. This study is designed to explore just that.

The DANTE study is investigating a strategy where patients who have been stable on their initial CML medication (Tasigna) might be able to gradually reduce or even stop their treatment. This is done in two stages, where doctors carefully monitor blood tests to see if the leukaemia remains controlled without daily medication. The aim is to achieve what's called a 'treatment-free remission' – essentially, being well without needing to take regular anti-cancer drugs.

If the leukaemia cells start to become detectable again during this treatment-free period, participants would go back on their medication or potentially switch to a combination of Tasigna and Scemblix. The study will carefully track how many people successfully stay in remission without treatment, how long this lasts, and what happens to those who need to restart or change their medication. This research is important because it could help understand if patients can safely achieve a better quality of life without continuous drug therapy, while still keeping their CML under control.

Pontos principais

  • The DANTE study explores if CML patients can stop medication.
  • It aims for a 'treatment-free remission' in two stages.
  • Participants take Tasigna and may later take Scemblix if needed.
  • Regular blood tests are crucial to monitor leukaemia levels.
  • The study could lead to new ways of managing CML without lifelong drugs.
  • You can always choose to leave the study.

Quem pode ser elegível?

To be considered for this study, you must be an adult aged 18 or older. Both men and women are welcome to participate. The study is specifically for people who have chronic myeloid leukaemia (CML).

There are also specific medical requirements related to your CML and how you've been treated so far. For example, your leukaemia needs to have responded well to your current medication (nilotinib, also known as Tasigna) for a certain period, and your blood test results for the leukaemia cells (called BCR-ABL levels) need to be very low and stable.

Your study doctor will discuss all the detailed criteria with you to make sure this trial is the right fit. They will check your medical history, current health, and past CML treatments to see if you meet all the necessary requirements.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have Chronic Myeloid Leukaemia (CML)?
  3. Have you been taking Tasigna (nilotinib) as your first treatment?
  4. Have your CML blood test results (BCR-ABL levels) been very low and stable for a while?
  5. Are you willing to attend regular clinic appointments for blood tests and check-ups?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join the DANTE study, you will initially be taking a medication called Tasigna (nilotinib). The study involves a careful process of potentially reducing and then stopping this medication in two stages, aiming for a 'treatment-free' period. Throughout these stages, you'll have regular blood tests to monitor your leukaemia cells (BCR-ABL levels).

If your leukaemia cells become detectable again during a treatment-free stage, you would restart Tasigna or potentially switch to a combination of Tasigna and Scemblix. The study will involve frequent visits to the clinic for these blood tests and to check on your overall health. The total duration of your participation will depend on how you respond to the treatment de-escalation and remission stages, but it will involve several years of follow-up.

Riscos e benefícios potenciais

Participating in this study might offer the benefit of potentially stopping your daily CML medication, which could improve your quality of life by reducing side effects and the burden of continuous treatment. However, there's a risk that your leukaemia might become detectable again if you stop treatment, meaning you would need to restart medication, possibly at a higher dose or with a different combination. There could also be side effects from the medications used. You have the full right to withdraw from the study at any time, for any reason, without affecting your standard medical care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Itália

Perguntas frequentes

What is CML?

CML stands for Chronic Myeloid Leukaemia. It's a type of cancer that affects the blood and bone marrow, where a specific genetic change leads to the production of too many white blood cells.

What does 'treatment-free remission' mean?

It means your leukaemia is controlled and undetectable even though you are not taking regular medication. The goal is to see if you can remain healthy without daily drugs.

What medications are involved?

The main medications involved are Tasigna (nilotinib) and Scemblix (asciminib). These are taken as tablets or capsules.

What happens if my leukaemia comes back?

If your leukaemia cells become detectable during a treatment-free period, you would restart your medication, potentially with a switch or a combination of Tasigna and Scemblix.

Quanto tempo durará o estudo?

The study involves several years of monitoring, including different stages of treatment reduction and follow-up, depending on your individual response.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A phase II, single-arm study of de-escalation and treatment-…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.